ESTRO 2025 - Abstract Book

S1929

Clinical - Urology

ESTRO 2025

was 89.5% (95% CI 87.0-93.2). The freedom from BF, DM and CSS were 84.4% (95% CI 80.2-87.8), 93.5% (95% CI 90.4 95.6) and 97% (95% CI 94.7-98.6) respectively. In multivariate MVA, after adjusting for patient age, T stage, ISUP group, initial PSA level, and hormone therapy, a higher radiotherapy dose remained significantly associated with improved overall survival (OS) (HR 3.13, 95% CI 1.67-5.90) and cancer-specific survival (CSS) (HR 3.98; 95% CI 1.20 13.26).

Conclusion: Intensified therapy with high-dose EBRT combined with ADT provides excellent 10-year outcomes in HRPCa. A high radiation dose is crucial for effective treatment of high-risk disease.

Keywords: Prostate cancer, radiation dose, horone therapy

References: Zapatero A, Guerrero A, Maldonado et al. High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial. Lancet Oncol. 2022 May;23(5):671-681. doi: 10.1016/S1470-2045(22)00190-5. Epub 2022 Apr 12. PMID: 35427469. Christophe Hennequin, Paul Sargos, Lise Roca, et al. SLong-term results of dose escalation (80 vs 70 Gy) combined with long-term androgen deprivation in high-risk prostate cancers: GETUG-AFU 18 randomized trial.. JCO 42 , LBA259-LBA259(2024). DOI:10.1200/JCO.2024.42.4_suppl.LBA259

1331

Digital Poster Phase II randomized controlled trial of dose-escalated SBRT for prostate cancer: focal dose escalation versus peripheral dose escalation. Koji Inaba 1 , Yoshihiko Manabe 2 , Hideyasu Tsumura 3 , Masahiro Nakano 4 , Ryohei Sasaki 5 , Akifumi Kajihara 5 , Daisuke Miyawaki 5 , Akitomo Sugawara 6 , Tsuyoshi Fukuzawa 6 , Toshihisa Kuroki 6 , Shinya Neri 7 , Masashi Nozue 7 , Tsuyoshi Kato 7 , Natsuo Tomita 8 , Masanari Niwa 8 , Kazumasa Odagiri 9 , Mizuki Sato 9 , Yuya Tabuchi 9 , Masato Nishitani 10 , Hiroshi Igaki 1 , Hiromichi Ishiyama 4 1 Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan. 2 Radiation Oncology, Nanbu Tokushukai Hospital, Okinawa, Japan. 3 Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan. 4 Department of Radiation Oncology, Kitasato University School of Medicine, Kanagawa, Japan. 5 Division of Radiation Oncology, Kobe University Hospital, Kobe City, (Hyogo), Japan. 6 Department of Radiation Oncology, Tokai University